MedTrace Logo

Dinalbuphine Sebacate in Postoperative Pain Control After TKA

NCT07140510 · Status: NOT_YET_RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-08-24

No results posted yet for this study

Summary

To evaluate the effectiveness of Dinalbuphine Sebacate for controlling subacute pain after total knee arthroplasty

Conditions

  • Osteo Arthritis of the Knee
  • Total Knee Anthroplasty

Interventions

DRUG

Dinalbuphine Sebacate

Dinalbuphine Sebacate 150 mg intramuscular injection after spinal anesthesia and adductor canal block in the same side of TKA

DRUG

Normal Saline

Normal saline 2 mL intramuscular injection after spinal anesthesia and adddutor canal block

Sponsors & Collaborators

  • Thammasat University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-31
Primary Completion
2026-06-30
Completion
2026-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07140510 on ClinicalTrials.gov